<unk>  is a tyrosine kinase inhibitor that is FDA approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia.   Common adverse reactions include myelosuppression, fluid retention, diarrhea, headache, dyspnea, rash, fatigue, nausea, and hemorrhage.
Dasatinib
Neratinib
Fostamatinib
Afatinib
Brigatinib
Lenvatinib
Lorlatinib
Dabrafenib mesylate